BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 1708601)

  • 1. [Proliferation-associated antigens PCNA and Ki-67 in two- and three-dimensional experimental systems of human squamous epithelial carcinomas].
    Knüchel R; Hofstaedter F; Sutherland RM; Keng PC
    Verh Dtsch Ges Pathol; 1990; 74():275-8. PubMed ID: 1708601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocytochemical detection of cell proliferation-related antigens in cytologic smears of human malignant neoplasms using PC10, reactive with proliferating cell nuclear antigen, and Ki-67. A comparative study.
    Pelosi G; Bresaola E; Manfrin E; Rodella S; Schiavon I; Iannucci A
    Arch Pathol Lab Med; 1994 May; 118(5):510-6. PubMed ID: 7910728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma.
    Tanioka F; Hiroi M; Yamane T; Hara H
    Zentralbl Pathol; 1993 Aug; 139(3):185-93. PubMed ID: 8105885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation indices in spontaneous canine lung cancer: proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts.
    Griffey SM; Kraegel SA; Madewell BR
    J Comp Pathol; 1999 May; 120(4):321-32. PubMed ID: 10208729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative flow cytometric analysis of Ki-67 and proliferating cell nuclear antigen (PCNA) in solid neoplasms.
    Steck K; el-Naggar AK
    Cytometry; 1994 Nov; 17(3):258-65. PubMed ID: 7851161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparison of proliferating cell nuclear antigen immunostaining, nucleolar organizer region staining in lung cancer].
    Zhao T; Zhang YL; Li CD
    Zhonghua Jie He He Hu Xi Za Zhi; 1993 Dec; 16(6):342-4, 374. PubMed ID: 7913415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients.
    Ishida T; Kaneko S; Akazawa K; Tateishi M; Sugio K; Sugimachi K
    Cancer Res; 1993 Oct; 53(20):5000-3. PubMed ID: 8104690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of cell cycle-related Ki-67 and p120 expression by flow cytometric BrdUrd-Hoechst/7AAD and immunolabeling technique.
    Endl E; Steinbach P; Knüchel R; Hofstädter F
    Cytometry; 1997 Nov; 29(3):233-41. PubMed ID: 9389440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.
    Khine MM; Aung W; Sibbons PD; Howard CV; Clapham E; McGill F; Van Velzen D
    Lab Invest; 1994 Jan; 70(1):125-9. PubMed ID: 7905542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.
    Ioachim E; Peschos D; Goussia A; Mittari E; Charalabopoulos K; Michael M; Salmas M; Vougiouklakis T; Assimakopoulos D; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Jun; 23(2):277-83. PubMed ID: 15354413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCNA/cyclin expression in transitional cell carcinomas of the human bladder: its correlation with Ki-67 and epidermal growth factor receptor immunostainings.
    Serio G
    Pathologica; 1994 Apr; 86(2):161-6. PubMed ID: 7936759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical evidence for the expression of proliferating cell nuclear antigen (PCNA) by non-proliferating hepatocytes adjacent to metastatic tumours and in inflammatory conditions.
    Harrison RF; Reynolds GM; Rowlands DC
    J Pathol; 1993 Oct; 171(2):115-22. PubMed ID: 7904308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of suramin on expression of proliferation associated nuclear antigens in DU-145 prostate carcinoma cells.
    Qiao L; Pizzolo JG; Melamed MR
    Biochem Biophys Res Commun; 1994 Jun; 201(2):581-8. PubMed ID: 7911660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
    Narita T; Funahashi H; Satoh Y; Takagi H
    Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferating cell nuclear antigen in archival surgical specimens of malignant lymphoma and metastatic carcinoma: immunohistochemical and flow cytometric analysis.
    Gorczyca W; Kram A; Tuziak T; Darzynkiewicz Z; Melamed MR
    Patol Pol; 1993; 44(3):121-8. PubMed ID: 7902557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
    Cheville JC; Terrell RB; Cohen MB
    Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of immunohistochemical staining of proliferating cells in paraffin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen.
    Yu CC; Dublin EA; Camplejohn RS; Levison DA
    Anal Cell Pathol; 1995 Jul; 9(1):45-52. PubMed ID: 7577754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA analysis of head and neck squamous cell carcinoma by flow cytometry.
    Lampe HB
    Laryngoscope; 1993 Jun; 103(6):637-44. PubMed ID: 8099190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors.
    Bodey B; Bodey B; Gröger AM; Siegel SE; Kaiser HE
    Anticancer Res; 1997; 17(1A):189-96. PubMed ID: 9066650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.